Adaptive Biotechnologies (ADPT) Q2 2023: ClonoSeq Test Volumes Up 52% as MRD Penetration Accelerates

August 2, 2023 | By EarningsIQ Research

ClonoSeq, minimal residual disease (MRD) testing, delivered standout 52% volume growth, confirming Adaptive’s execution on clinical penetration and demand. Immune medicine revenue steadied on milestone contributions, while cost discipline and margin improvement signal a credible path to profitability. Management’s focus on payer coverage, Epic integration, and milestone-driven partnerships sets up a back-half loaded year with operational and reimbursement catalysts ahead.

Summary

• ClonoSeq Volume Expansion: MRD test adoption broadened across indications and channels, reinforcing market leadership.
• Margin and Cost Leverage: Sequencing efficiency and milestone revenue drove sequential margin gains and lower cash burn.
• Back-Half Catalysts: Epic integration, payer progress, and drug discovery deals position Adaptive for a pivotal H2.

Business Overview

Adaptive Biotechnologies is a precision medicine company leveraging immune-driven sequencing to detect, monitor, and treat disease. Its business is anchored in two segments: MRD (minimal residual disease) testing—primarily through ClonoSeq, which tracks residual cancer in blood and bone marrow—and immune medicine, which partners with pharma for drug discovery and clinical trial services. Revenue is generated from clinical test volume, pharma partnerships, and milestone payments tied to R&D collaborations.

Performance Analysis

Adaptive’s Q2 featured robust operational execution, headlined by ClonoSeq test volumes growing 52% year-over-year to 13,664 delivered tests. MRD revenue now comprises 53% of total revenue, with clinical testing and pharma partnerships both contributing. Immune medicine, at 47% of revenue, was buoyed by a $7.8 million IND milestone from Genentech, offsetting anticipated declines in amortization and pharma services softness.

Gross margin improved sequentially by 13 percentage points, reaching 63%, driven by milestone revenue and lab cost reductions. Operating expenses declined 5% year-over-year, reflecting disciplined R&D investment and organizational streamlining. Cash preservation remains a priority, with quarterly burn now expected at $35 million, down from $40 million previously forecasted.

• Test Mix Shift: Blood-based MRD testing now represents 37% of all MRD tests, up from prior quarters, signaling a shift toward less invasive monitoring.
• Community Penetration: Community accounts contributed 21% of ClonoSeq volume, up from 11% a year ago, accelerating non-academic adoption.
• ASP Headwinds: Average selling price (ASP) pressure from out-of-policy tests and higher Medicaid mix weighed on MRD revenue per test, though management outlined a targeted plan to reverse this trend.

Pharma services growth moderated due to macro-driven trial delays and industry reprioritization, but bookings remain healthy and management reiterated confidence in a 20% CAGR over five years for this business.

Executive Commentary

Strategic Positioning

1. MRD Leadership and Penetration

Adaptive’s MRD franchise, led by ClonoSeq, is expanding across indications and care settings. The company is driving volume through both academic and community channels, with community accounts now representing over one fifth of volume. Blood-based MRD testing is gaining traction, which could increase addressable market and reduce barriers to adoption.

2. ASP Recovery and Payer Strategy

Management is prioritizing payer contracts, prior authorization workflows, and claim management to address ASP leakage. Out-of-policy testing and Medicaid mix pressured ASPs, but initiatives are in place to close policy gaps and improve collections. Leadership reiterated a long-term target of $1,600 ASP by 2027, with sequential improvement expected in the second half of 2023.

3. Epic Integration and Digital Enablement

Integration with Epic’s EMR (electronic medical record) system is a strategic lever for test ordering efficiency and scale. Initial pilot sites are live, with broader rollout expected to drive incremental volume in 2024 and beyond. This integration will streamline clinician workflow and could accelerate both adoption and reimbursement.

4. Drug Discovery and Partnership Milestones

Milestone revenue from Genentech’s IND acceptance validates Adaptive’s TCR (T-cell receptor) discovery platform. The company anticipates additional drug discovery deals in Q4, which are already factored into annual guidance. Progress in personalized cell therapy and autoimmune target discovery with Genentech and internal R&D provides optionality for future growth and milestone upside.

5. Cost Discipline and Margin Expansion

Gross margin improvement was driven by milestone revenue, lab cost controls, and sequencing efficiency. The company is evaluating a shift from NextSeq to NovaSeqX sequencing platforms to further lower costs. Operating expenses are being tightly managed, supporting a credible path to profitability and cash break-even by 2026.

Key Considerations

Q2 marked a transition quarter where Adaptive demonstrated operational leverage, strategic execution on MRD penetration, and incremental progress on digital and pharma partnership fronts.

Key Considerations:

• Volume-Driven Growth: Sustained double-digit ClonoSeq volume increases are offsetting ASP headwinds, but pricing recovery is needed for durable margin expansion.
• Reimbursement Complexity: Medicaid mix, out-of-policy tests, and payer prior authorization hurdles remain near-term ASP risks, though management’s multi-pronged approach targets reversal by year-end.
• Pharma Macro Drag: Clinical trial delays and portfolio reprioritization in biopharma have tempered near-term pharma services growth, though diversification across 120 trials and 60 companies provides some insulation.
• Digital Integration Ramp: Epic EMR integration is a multi-year effort, with meaningful volume impact likely to materialize in 2024 and beyond as site onboarding accelerates.
• Cash and Margin Trajectory: Lower cash burn and sequential margin gains bolster the path to profitability, but continued execution on cost control and revenue mix is critical.

Risks

Adaptive faces reimbursement uncertainty, with near-term ASP pressure from payer mix and policy gaps. Macro-driven delays in pharma services and trial enrollment could persist, impacting milestone timing and revenue visibility. Execution risk around Epic integration and payer contracting remains, while competitive pressure in MRD testing could intensify as peers address similar reimbursement challenges. Management’s guidance assumes successful execution on operational and strategic initiatives, which may face unforeseen obstacles.

Forward Outlook

For Q3, Adaptive expects:

• MRD revenue growth to accelerate, driven by ClonoSeq volume and back-half milestones
• Pharma services and drug discovery revenue to be weighted toward Q4, with new deals anticipated

For full-year 2023, management reiterated guidance:

• Total revenue of $205 to $215 million, with 55% from MRD and 45% from immune medicine
• ClonoSeq test volume growth of over 50% versus 2022
• Operating expenses, including cost of revenue, below 2022 levels

Management highlighted several factors that will shape H2:

• Execution on payer contracting and ASP recovery initiatives
• Completion of key Epic EMR integrations and broader rollout
• Closure of drug discovery deals and realization of milestone revenue

Takeaways

Adaptive’s Q2 showcased strong operational momentum in MRD, credible margin progress, and a back-loaded revenue cadence tied to execution on reimbursement, digital integration, and pharma partnerships.

• MRD Penetration Surged: ClonoSeq’s 52% volume growth and expanding blood-based test mix solidify Adaptive’s leadership and drive addressable market expansion.
• Margin and Cash Inflection: Sequencing efficiency, milestone revenue, and cost discipline improved margin structure and reduced cash burn, building confidence in the path to profitability.
• Watch for H2 Catalysts: Payer contract wins, Epic integration scale, and pharma milestone realization will be decisive for sustaining growth and margin trajectory into 2024.

Conclusion

Adaptive Biotechnologies delivered a quarter of operational progress, margin improvement, and strategic clarity, with ClonoSeq test adoption outpacing expectations. The company’s focus on payer coverage, digital enablement, and pharma partnerships sets up a catalyst-rich back half, but continued execution on reimbursement and cost leverage remains critical for long-term value creation.

Industry Read-Through

Adaptive’s experience underscores both the opportunity and challenge for diagnostics and precision medicine companies scaling clinical adoption in complex payer and provider environments. The company’s ASP headwinds mirror broader reimbursement pressures facing MRD and molecular diagnostics peers, while its digital integration with Epic highlights the growing importance of EMR connectivity for test uptake and workflow efficiency. Pharma services exposure to clinical trial delays and pipeline reprioritization is a cautionary signal for other platform players relying on milestone-driven revenue. Investors should monitor how digital enablement, payer contracting, and milestone economics shape the competitive landscape for precision diagnostics and immune-driven drug discovery.

ADPT Healthcare Diagnostics Precision Medicine MRD ClonoSeq Pharma Partnerships Reimbursement